SUNNYVALE, Calif.–(BUSINESS WIRE)–Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced that multiple podium presentations at the upcoming VEITHsymposium Nov. 13-17 at the New York Hilton-Midtown will feature the company’s TransCarotid Artery Revascularization (TCAR) procedure. One-year results from the Society […]
Peripheral/Endo
Hemostemix Announces Important Manufacturing Process Refinements
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its manufacturing process, which will result in an approximate 40% reduction in manufacturing time for its lead product ACP-01. As disclosed […]
BD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial
FRANKLIN LAKES, N.J., Nov. 7, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication. The clinical study is a prospective, global, multicenter, randomized, controlled trial comparing the […]
XableCath Catheters Demonstrate Ability to Cross Chronic Venous Occlusions
SALT LAKE CITY–(BUSINESS WIRE)–XableCath, a commercial-stage medical device company, announced today that it has demonstrated initial safety and efficacy of its unique catheters for use with chronic venous occlusions, commonly characterized by recalcitrant lesions that have historically proven difficult to cross with standard catheter technologies. XableCath catheters are FDA-cleared for […]
12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company’s SurVeil® drug-coated balloon (DCB) was shared in a late-breaking clinical trial presentation at the Vascular Interventional Advances (VIVA) 2018 […]
iDissection Classification Study to Evaluate Dissection Rate of FLEX Dynamic Scoring Catheter™
• New study to determine if the FLEX Dynamic Scoring Catheter™ reduces dissections and the need for bailout stents in peripheral arteries • 15 patients to be evaluated by Dr. Nicolas W. Shammas at the UnityPoint Trinity in Bettendorf, Iowa • More than 12 million people in the US and […]
Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial successfully achieved both primary and secondary endpoints. One year results from the TOBA II study were presented […]
Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials
(GLOBE NEWSWIRE via COMTEX) –New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD DUBLIN and LAS VEGAS – November 6, 2018 – Medtronic plc (NYSE:MDT) data presented today reinforce the durability, safety, and effectiveness of the IN.PACT(TM) Admiral(TM) drug-coated balloon […]
Micro Medical Solutions’ New MicroStent with 120 cm Delivery Catheter Receives CE Mark Approval
WILMINGTON, Mass., Nov. 5, 2018 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions designed to improve clinical outcomes and quality of life, announced today that it has received CE Mark approval for a 4Fr.-compatible MicroStent 120 cm delivery catheter, as well as MicroStent devices in five […]
Preclinical Safety Studies Demonstrate That Drug Presence Can Accentuate Pathological Responses at Stent Fracture Sites
LEXINGTON, Mass.–(BUSINESS WIRE)–CBSET, a non-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, announced today that its scientists have published data and analyses (“Fracture in drug-eluting stents increases focal intimal hyperplasia in the atherosclerosed rabbit iliac artery”) that “illustrate differences in the dynamic healing responses […]



